The Doctors at Ophthalmology Associates are excited to be investigators for this revolutionary new treatment for Keratoconus and corneal ectasia. For more detailed information about this treatment please visit www.cxlusa.com or call the office at 314 966-5000.
BREAKING NEWS: Five-year data shows CXL can stop keratoconus progression
This prospective study evaluated long-term results of corneal collagen cross-linking (CXL) with ultraviolet A irradiation and riboflavin in 32 patients (40 eyes) with grades I through III progressive keratoconus. At five years, CXL halted disease progression, stabilized UCVA, refraction, corneal thickness, corneal power and posterior elevation. Improvements also were noted in BCVA and anterior elevation. One patient dropped out due to an increase in BCVA and an inability to tolerate contact lenses or spectacles. No safety issues were noted. Ophthalmology, August 2013
NEW STANDARD: CXL should be considered in all patients with progressive keratoconus or corneal ectasia
Investigators analyzed a cohort of 104 eyes to determine preoperative characteristics that may influence outcomes from corneal collagen crosslinking (CXL) treatment. No factor was independently predictive of CXL failure. In general, eyes with worse CDVA and higher maximum K readings were more likely to improve. They conclude that all eyes be considered for treatment with the goal of stabilizing disease progression. Patients and physicians should be aware of the risk for loss of visual acuity, particularly in eyes with a preoperative CDVA better than 20/40.
Journal of Cataract & Refractive Surgery, August 2013